logo
Plus   Neg
Share
Email

AstraZeneca, Daiichi Sankyo: Phase II DESTINY-Breast01 Trial Met Primary Goal

British drug major AstraZeneca Plc (AZN.L,AZN) and Daiichi Sankyo Co. Ltd. (DSKYF.PK) on Wednesday announced that the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201) met primary endpoint.

DESTINY-Breast01 is a pivotal Phase II, open-label, global, multicentre, two-part trial of trastuzumab deruxtecan. The HER2-targeting antibody drug conjugate or ADC and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine.

The companies expect the positive top-line results to support planned global regulatory submissions, including a Biologics License Application with the US Food and Drug Administration or FDA, anticipated in the second half of 2019.

Trastuzumab deruxtecan has been granted US FDA Breakthrough Therapy Designation and Fast Track Designation for HER2-positive patients in the advanced or refractory breast cancer setting.

José Baselga, Executive Vice President, R&D Oncology, said, "We are encouraged to see positive data from trastuzumab deruxtecan, with the DESTINY-Breast01 trial now reinforcing what earlier data have shown. …. we are eager to bring it as quickly as possible to patients with refractory HER2-positive breast cancer who continue to have high unmet medical need."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Zoom Video Communications (ZM) gained 4% on extended session Tuesday after the video conferencing software company reported a first-quarter results that trumped Wall Street estimates and issued a outlook for the second and full year 2021 that is expected to beat current expectations. First-quarter... The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products.
Follow RTT